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UVB is widely used to treat psoriasis. Conventional broadband UVB lamps are less effective than narrowband
UVB lamps, which have an emission peak at 311 nm. The long-term safety of narrowband UVB phototherapy is
uncertain. ‘‘Selective’’ broadband UVB lamps, which have little emission o290 nm, are also available, but have
not been adequately compared to narrowband UVB lamps. We performed a randomized comparison of
narrowband UVB (TL-01 lamps) and selective broadband UVB (UV6 lamps) in 100 patients with psoriasis. The
median number of exposures for clearance was 28.4 for TL-01 and 30.4 for UV6 (ratio of the medians 0.93; 95%
confidence interval (CI) 0.80, 1.09; P¼ 0.39). No significant difference was found in the proportion of patients
achieving clearance: TL-01 56%, UV6 40% (odds ratio for clearance with TL-01 relative to UV6 was 2.00 (95% CI
0.87, 4.62), P¼ 0.10). Side effects, including the development of erythema during phototherapy, were similar for
the two lamp types. Risk estimates based on the human photocarcinogenesis action spectrum predict that
narrowband UVB lamps will be 50% more carcinogenic for equal erythemal doses than selective broadband
lamps (UV6). As these two lamp types appear to be of similar efficacy, phototherapy using a selective broadband
source may be a safer option than use of narrowband UVB.
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INTRODUCTION
UVB, either alone or in combination with topical agents, has
been used to treat psoriasis for many decades (Anderson
et al., 1984). Typically, fluorescent lamps were used with a
broad spectral emission including some wavelengths
o290 nm, within the UVC waveband (for example: FS20,
Westinghouse, Pittsburgh PA; TL-12, Philips, Eindhoven, the
Netherlands). Pioneering work by Parrish and Jaenicke (1981)
on the action spectrum for clearance of psoriasis showed that
wavelengthso290 nm, although erythemogenic, were thera-
peutically ineffective. Subsequently, a novel fluorescent lamp
was developed with a narrow emission peak around 311 nm
(TL-01, Philips) and only 0.1% of its output o290 nm
(Figure 1) (Ibbotson et al., 2004). Several small-scale clinical
studies have shown an improved response of psoriasis to this
narrowband lamp compared with conventional broadband
phototherapy (van Weelden et al., 1988; Storbeck et al.,
1993; Coven et al., 1997; Walters et al., 1999). Narrowband
UVB phototherapy is now used widely in the UK, continental
Europe, and increasingly in the USA (Zanolli, 2003; Ibbotson
et al., 2004).
Some concern has been raised about the potential
carcinogenic risk of narrowband UVB. Young (1995)
summarized data from murine studies (van Weelden et al.,
1988; Flindt-Hansen et al., 1991; Wulf et al., 1994; Gibbs
et al., 1995) as indicating that narrowband UVB may be two
to three times more carcinogenic per minimal erythema dose
(MED) than conventional broadband UVB. It was suggested
(Young, 1995) that any increased cancer risk would be
negated by the increased efficacy of narrowband UVB.
However, although clinical trials have shown that narrow-
band UVB is more effective than broadband UVB, the actual
differences in response to treatment are relatively small.
Therefore, the relative risk of narrowband UVB phototherapy
compared to broadband remains uncertain, particularly as
follow-up studies of patients are still of short duration
(Weischer et al., 2004; Man et al., 2005).
As well as the archetypal conventional broadband UVB
sources (FS20, TL-12), fluorescent lamps with relatively little
emission o290 nm are also available. That these so-called
‘‘selective’’ broadband sources would be effective to treat
psoriasis was predicted by Parrish and Jaenicke (1981). We
are not aware of any murine studies comparing directly the
non-melanoma cancer risk of selective broadband lamps with
either conventional broadband UVB or narrowband UVB
lamps. In the absence of such information, another method of
predicting skin cancer risk for a particular lamp is to use the
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photocarcinogenesis action spectrum published as an inter-
national Standard by the Commission Internationale de
l’Eclairage (CIE). The recent standard (CIE, 2006) is derived
from experimental animal data and is modified to estimate
the non-melanoma tumor response in human skin.
By combining the spectral power distribution of a specific
lamp with the action spectra for both erythema (CIE, 1998) and
photocarcinogenesis (CIE, 2006), it is possible to calculate the
carcinogenic risk per unit erythemal dose. The results of these
calculations indicate that narrowband UVB lamps will be 1.5
times more carcinogenic than selective broadband UVB
lamps. Whether selective broadband UVB phototherapy is
likely to be a safer option than narrowband UVB clearly
depends on the relative efficacy of the two lamp types in
treating psoriasis. We are not aware of any studies comparing
selective broadband and narrowband UVB where clearance of
psoriasis has been used as an end point. We have therefore
performed a randomized, observer-blinded comparison of
these light sources in 100 patients with psoriasis.
RESULTS
Participant flow
Patients were recruited between May 2003 and November
2004, with the follow-up assessments completed by June
2005. Baseline characteristics of the two treatment groups are
shown in Table 1 and the trial profile is shown in Figure 2. Of
the 192 sequential patients screened for inclusion, 68 were
excluded under the protocol exclusion criteria, 18 refused to
take part in the trial, and in six patients a medical decision
was made by the phototherapy clinician to assign the patient
to one or other treatment. Thus, 100 patients were
randomized, 50 being assigned to TL-01, and 50 to UV6.
Analysis
Number of exposures for clearance. The median number of
exposures for clearance, based on fitting a Weibull distribu-
tion (Figure 3) and adjusting for stratification variables, was
28.4 for TL-01 and 30.4 for UV6 (ratio of the medians
estimated as 0.93; 95% confidence interval (CI) 0.80, 1.09;
P¼0.39). The residual plots and Figure 3 indicated that the
Weibull distribution provided a good fit for these data. The
model also showed that patients with skin type III/IV cleared
faster than those with skin type I/II (see Table 2 for details).
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Figure 1. Emission spectra of the two lamps. The emission spectra of the
selective broadband lamp (UV6) (solid line) and narrowband lamp (TL-01)
dashed line.
Table 1. Baseline characteristics of the patients
randomized to receive narrowband UVB (TL-01) and
selective broadband UVB (UV6)
TL-01 UV6
Mean age (years) (range) 42 (19–76) 39 (17–77)
Sex 25M 25F 20M 30F
Mean baseline PASI score (range) 7.5 (2.1–27.9) 6.1 (2.7–21.7)
F, female; M, male; PASI, psoriasis area and severity index.
192 patients screened for eligibility
68 failed to meet eligibility criteria
18 refused to take part
6 non-randomized by clinician
100 randomized
50 assigned to recieve UV650 assigned to recieve TL-01
9 withdrew:6 withdrew:
8 failed to attend3 failed to attend
after 1, 6, 10, 14,after 1, 10 and 27
14, 17, 24 and 29
treatments.
treatments.
1 withdrew
because of side
effect.
41 completed trial44 completed trial
3 withdrew
because of side
effects.
50 included in analysis50 included in analysis
Figure 2. The trial profile.
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Figure 3. Probability of non-clearance with the two lamps. Survival curves
showing the probability of non-clearance of psoriasis during treatment with
narrowband UVB (TL-01) (dashed lines) and selective broadband UVB (UV6)
(solid lines). The stepped lines are Kaplan–Meier plots, with censored
observations indicated by the small vertical tick marks. The smooth curves are
fitted Weibull curves for each lamp, plotted at the mean values of the
stratifying factors.
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Cumulative dose for clearance. Based on fitting a Weibull
distribution, the median (quartiles) of the cumulative dose to
clearance, were estimated as 40.9 (28.1, 55.2) J/cm2 (TL-01)
and 39.9 (27.4, 53.6) J/cm2 (UV6).
Clearance. Clearance of psoriasis was achieved in 28/50
(56%) of those receiving TL-01 compared with 20/50 (40%)
of those receiving UV6. The odds ratio for clearance with
TL-01 relative to UV6, adjusted for the factors used to stratify
the allocation, was 2.00 (95% CI 0.87, 4.62), P¼0.10. The
odds of clearance with respect to the stratifying factors are
shown in Table 2.
PASI scores in non-clearers. In order to see whether there
was a difference in clinical response to the two lamp types in
the patients who did not clear, we examined the last available
psoriasis area and severity index (PASI) scores for all of the
‘‘non-cleared’’ patients, irrespective of the reason for non-
completion. As this comparison involves groups not balanced
by randomization, the baseline PASI scores for these patients
were also analyzed to assess the comparability of the groups.
The results are shown in Table 3. The corresponding
comparisons among patients who failed to clear but made
planned exits from the trial are also given in Table 3. It should
be stressed that these are not randomized comparisons and
should be interpreted with caution.
Side effects. A degree of erythema was noted at some stage in
the treatment course in 43 patients treated with TL-01 and 42
treated with UV6. In only two patients treated with TL-01 and
three treated with UV6 was the erythema of sufficient severity
to cause them to miss treatments. Polymorphic light eruption
occurred in three patients treated with TL-01, (two of whom
withdrew as a result (Figure 2)) and in one patient treated
with UV6. Pruritus occurred in two patients treated with
UV6, and one withdrew as a result (Figure 2). Inflammatory
psoriasis developed early in the course in one patient treated
with each lamp type. Both patients withdrew (Figure 2) as
topical corticosteroids were required to allow them to
continue with phototherapy.
Follow-up. The number of patients remaining clear of
psoriasis when examined 3 and 6 months after completing
phototherapy is shown in Table 4.
DISCUSSION
In this randomized study, we have found no evidence of a
difference between those treated with selective broadband
UVB and those treated with narrowband UVB in terms of
median number of treatments to clear, proportions of patients
achieving clearance and improvement in PASI for non-
clearers. The data are compatible with differences in
treatment outcome described by the CIs given above. For
the primary outcome, the median number of treatments to
clear, the difference is likely to be less than 20%. Although
this study is considerably larger than previous comparisons
involving narrowband UVB, the CI for the ratio of the odds of
clearing is quite wide.
Table 2. The effects of stratifying factors on the odds of clearance and the ratio of median number of exposures to
clearance for all patients considered together irrespective of the lamp type used for treatment
Comparison
Odds of
clearance 95% CI and P
Ratio of median
exposures to clearance 95% CI and P-value
Plaque size: large relative to small 0.71 0.30, 1.68 P=0.43 1.13 0.94, 1.35 P=0.19
Skin type: III/IV relative to I/II 3.22 1.40, 7.43 P=0.006 0.77 0.65, 0.91 P=0.02
Involvement of skin around or below
knees: No relative to yes
1.11 0.41, 3.02 P=0.84 0.90 0.74, 1.09 P=0.28
CI, confidence interval.
Table 3. The mean PASI scores in non-clearing patients at baseline (before treatment) and based on the last score
available for individual patients
Mean TL-01 (n) Mean UV6 (n) Difference and 95% CI P-value
Score at baseline
All patients failing to clear 7.4 (22) 6.8 (30) 0.6 (2.6, 3.9) 0.69
Patients failing to clear who made a planned exit from the trial 8.3 (16) 5.8 (21) 2.5 (1.4, 6.4) 0.20
Last PASI available
All patients failing to clear 3.8 (22) 3.9 (30) 0.0 (2.1, 2.1) 0.99
Patients failing to clear who made a planned exit from the trial 3.8 (16) 3.0 (21) 0.7 (1.5, 2.9) 0.50
CI, confidence interval; PASI, psoriasis area and severity index.
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The patients we studied were recruited from a photo-
therapy clinic where patients with psoriasis likely to require
phototherapy are referred. Although the patients had rela-
tively mild disease (as judged by the mean pretreatment PASI
score), they are probably representative of patients with
psoriasis receiving hospital-based phototherapy, particularly
as a high proportion of eligible patients screened for inclusion
actually entered the trial.
The two groups were well-matched in terms of baseline
PASI score, and were stratified according to factors we
anticipated might influence clearing. In fact, unlike in our
previous studies (Gordon et al., 1999; Sakuntabhai et al.,
1993), plaque size did not appear to influence outcome
(Table 2), nor did involvement of the legs around or below
the knees, an area usually considered fairly resistant to
treatment (Waterston et al., 2004). However, patients of skin
type III/IV had a significantly greater chance of clearing than
those of skin type I/II.
We attempted to ensure that equal erythemal doses were
given, irrespective of lamp type used for treatment, by
measuring each patient’s MED before commencement of the
study (Gordon et al., 1998, 1999), and by using the same
percentage-based dose increases. That 85% of patients
developed erythema during the course of phototherapy
suggests that our treatment doses were adequate. The
clearance rate of 56% that we achieved with narrowband
UVB is within the range of values reported in previous studies
(29–90%) (Alora and Taylor, 1997; Dawe et al., 1998;
Wainwright et al., 1998; Gupta et al., 1999; Leenutaphong
et al., 2000; Yones et al., 2006). We were strict with regard to
criteria by which patients were categorized as ‘‘clear’’ (see
Materials and Methods). Nevertheless, the point at which
‘‘clearance’’ is achieved in an individual patient, or the
sometimes used end point of ‘‘minimal residual activity’’, is
subjective and imprecise. This underscores the need for the
evaluating physician to be blinded to treatment allocation
and treatment supervision, as was the case with our study.
Our follow-up data (Table 4) show the disappointingly high
relapse rate with UVB phototherapy, whichever lamp is used
for treatment.
Although there have been a large number of small-scale
studies comparing narrowband UVB and conventional
broadband UVB (reviewed by Dawe, 2003), we are aware
of only two studies involving selective UVB lamps (Karvonen
et al., 1989; Storbeck et al., 1993). In one of these (Karvonen
et al., 1989), all patients received dithranol in addition to
UVB. In the other study (Storbeck et al., 1993), 10 patients
with psoriasis received narrowband UVB to one-half of the
body and broadband UVB (UV6) to the other side. In eight of
the patients a better response was noted with narrowband
UVB, but the study was terminated whenever a difference
between the two sides of the body was noted, rather than at
clearance, and the mean number of exposures was only 10.
Parrish and Jaenicke (1981), in their seminal work on the
action spectrum for clearance of psoriasis, found that
wavelengths less than 290 nm, whilst highly erythemogenic,
were not effective in clearing psoriasis. The authors also
suggested that these findings could account for the improved
effectiveness of selective compared with conventional broad-
band UVB phototherapy. The TL-12 lamp, as an example of a
conventional broadband UVB, emits 5.5% of its output at less
than 290 nm, compared with 0.5% for UV6 and 0.1% for
TL-01 (Ibbotson et al., 2004). When the lamps’ spectra are
weighted according to the erythema action spectrum
(McKinlay and Diffey, 1987), the contribution to erythema
from radiation o290 nm is 21.8% (TL-12), 6.9% (UV6), and
2.3% (TL-01). We described previously (Diffey and Farr,
1987) a ‘‘phototherapy index’’, based on the Parrish and
Jaenicke (1981) action spectrum, which gave the predicted
efficacy of different lamp types at treating psoriasis (an index
o1 indicated that doses greater than the MED would be
required to clear psoriasis, whereas an index 41 indicated
that clearance could be achieved with suberythemal doses).
For minimal erythema treatment doses, the calculated
phototherapy indices were 0.6 (conventional broadband),
1.3 (selective broadband), and 1.5 (narrowband) (Diffey and
Farr, 1987; Diffey, 1990). It should be pointed out that the
action spectrum for clearance of psoriasis, and any predic-
tions based upon it, are subject to a good deal of uncertainty
as Parrish and Jaenicke (1981) only studied four patients, and
some of these appeared treatment resistant. Nevertheless, the
results of our clinical study showing no evidence of a
difference in response between selective broadband UVB and
narrowband UVB are in keeping with the findings of Parrish
and Jaenicke (1981).
The risks of narrowband UVB phototherapy will only
become apparent when long-term follow-up studies become
available, as was the case with psoralen photochemotherapy
(Stern and Lange, 1988). Presently available follow-up data
(Weischer et al., 2004; Man et al., 2005) are of too short
duration to contribute. Until clinical data become available,
the only method of risk estimation is to use the human
photocarcinogenesis action spectrum (CIE, 2006) derived
from modified murine experimental data. Based on this
action spectrum, relative to a conventional broadband UVB
source (FS20, TL-12), the selective broadband source (UV6)
has a carcinogenic potential that is 1.5 times greater, whereas
the narrowband UVB lamp is 2.3 times more carcinogenic
Table 4. Follow-up data showing the number of
patients who remained clear of psoriasis 3 and 6
months after completing phototherapy with
narrowband UVB (TL-01) and selective broadband
UVB (UV6)
TL-01 UV6
3 months
Number assessed 25 18
Number clear (% of those who
cleared) (% of those assessed)
4 (14.3) (16) 8 (40) (44.4)
6 months
Number assessed 19 13
Number clear (% of those who
cleared) (% of those assessed)
1 (3.6) (5.3) 0
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per MED; a figure in keeping with the estimate given by
Young (1995). The choice of lamp for UVB phototherapy
should be based on assessments of efficacy and potential
long-term hazards of treatment. Conventional broadband
lamps, although potentially safer, are probably of insufficient
efficacy to be recommended. Narrowband UVB lamps
(TL-01) although effective, are potentially 50% more carci-
nogenic for equal erythemal doses than selective broadband
lamps (UV6). Any increased carcinogenic risk is of concern
given the tendency of psoriasis to relapse rapidly after UVB
clearance (Table 4) (Yones et al., 2006) and the need for
repeated courses of treatment. If these two lamp types are
equally effective, or even if the selective broadband source is
slightly less effective at achieving clearance (as our results
possibly indicate), the selective broadband lamp may provide
the best balance between safety and efficacy for routine
clinical use.
MATERIALS AND METHODS
Protocol and study design
This was a single-center, observer-blinded, randomized study to
compare response of psoriasis to phototherapy using selective
broadband UVB (UV6, Sylvania, Raunheim, Germany) (Figure 1)
or narrowband UVB (TL-01). The study was approved by the
Newcastle and North Tyneside Local Research Ethics Committees,
registered as a clinical trial (ISRCTN61943529, http://www.con-
trolled-trials.com), conducted in accord with the Declaration of
Helsinki Principles, and participants gave written, informed consent.
Sample size estimation, as reported previously (de Berker et al.,
1997), suggested that for 80% power to detect a difference in median
number of treatments to clearance of 25% at the 5% significance
level, two groups of 50 patients would be required.
Patients
Patients with plaque-type psoriasis were recruited (by P.M.F.) from a
dedicated phototherapy clinic at a University Teaching Hospital. All
patients considered for UVB treatment of psoriasis were screened for
inclusion in the trial. The minimum age of entry was 18 years and
patients were excluded if they had received phototherapy or
systemic agents for psoriasis in the preceding 3 months.
UV phototesting and treatment
The MED for the appropriate lamp type was measured in each
patient. Phototesting was performed on the volar aspect of the
forearm using a device (Gordon et al., 1998) that allowed the
simultaneous delivery of 10 doses from either the TL-01 or UV6
lamp in a geometric series ranging from 0.2 to 1.6 J/cm2. The MED,
defined as the smallest dose of radiation required to achieve just
detectable erythema, was judged visually 24 hours after irradiation.
Patients were treated three times weekly with whole body
exposure units (UV7001, Waldmann, Villingen-Schwenningen,
Germany) fitted with 40 fluorescent lamps. The initial treatment
dose was 70% of the MED and the dose was increased after alternate
treatments by 40%, decreasing stepwise to 5% by the 18th
treatment. If erythema developed during treatment, depending on
the severity, planned dose increments were postponed or treatments
missed, until the erythema resolved. Emollients only were permitted
during the trial.
Dosimetry
Measurements of irradiance were made with a radiometer (IL 700,
International Light, Newburyport, MA) and UVB sensor, calibrated
spectroradiometrically, and statements of dose refer to unweighted,
spectrally integrated radiant exposure between 250 and 400 nm.
Assignment
Allocation of patients to treatment was stratified by three prognostic
factors namely:
1. predominant plaque size – defined as small (o3 cm diameter)
or large (43 cm) (Gordon et al., 1999);
2. involvement of skin on the legs around or below the knees (yes/
no);
3. skin type (I/II or III/IV).
Treatment allocation used opaque, sequentially numbered,
sealed envelopes (assembled by J.N.S.M.) and was based on
randomized permuted blocks within strata, with block lengths
randomly chosen as four or six. Envelopes were opened by
phototherapy nursing staff (supervised by S.L.) who then adminis-
tered the assigned treatment. Patients were aware of the treatment
they were receiving.
Assessments and masking
Clinical assessments of each patient were made immediately before
commencement of the course of phototherapy and then after every
six treatments (2 weeks) by a clinician (S.M.K.) who was blinded to
treatment allocation. These assessments were organized and
supervised by nursing staff, and the assessing clinician was only
permitted to judge clearance and grade the psoriasis severity using
the PASI scores (Fredriksson and Pettersson, 1978). Clearance was
defined as no residual psoriasis, or psoriasis only remaining in areas
shaded from UV exposure such as flexures. All clinical supervision
of the patients was carried out by phototherapy nurses and the
supervising dermatologist (P.M.F.). The primary hypothesis was to
compare the lamps with respect to the number of treatments to
clearance, and this was the primary outcome measure. Secondary
outcomes were clearance of psoriasis and PASI scores for non-
clearing patients. Patients who cleared during the study were
followed up at 3 and 6 months and assessed for continued clearance
or relapse.
Patients were encouraged to continue for at least 16 treat-
ments before a decision was made about lack of effectiveness of
the treatment, at which planned withdrawal was permitted.
No maximum number of treatments was specified for the trial
patients, but the phototherapy nurses followed a standard protocol
requiring evidence of continuing improvement to allow treatment to
continue beyond a total of 36 exposures. Patients who cleared,
and those who did not clear but received at least 16 exposures,
were judged to have completed the trial. Any patient making a
non-planned exit from the trial (by failing to attend for treatment), or
those who discontinued because of side effects were recorded as
‘‘failure to complete’’.
Statistical analysis
The principal analyses compare the treatment groups as formed by
randomization: patients who failed to complete were grouped with
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those who failed to clear. The primary outcome variable was the
number of visits to clearance and this together with the cumulative
UV dose for clearance were analyzed assuming a Weibull
proportional hazards survival model, with outcomes being the
number of exposures for clearance and cumulative UV dose for
clearance, with patients whose psoriasis did not clear considered to
be censored observations. The assumption of a Weibull distribution
was assessed by means of residual plots (Aitkin and Clayton, 1980)
and by superimposing fitted survival curves with distribution-free
estimators. Whether or not a patient cleared was analyzed using
logistic regression. All models included allocated treatment and the
stratification variables and were fitted using R (R Development Core
Team, 2005) and the R survival package. The PASI scores in non-
clearing patients were compared between treatments using t-tests.
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